

# Treatment-Resistant Depression Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034

*The Business Research Company's  
Treatment-Resistant Depression Global  
Market Report 2025 – Market Size,  
Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED  
KINGDOM, May 29, 2025

/EINPresswire.com/ -- The [treatment-resistant depression market size](#) has

grown significantly over recent years. From \$1.76 billion in 2024, it is projected to grow to \$1.88 billion in 2025 at a compound annual growth rate CAGR of 7.1%. This growth can be traced back to a rise in cases of treatment-resistant depression, an increased incidence of depression, better access to healthcare facilities, growing awareness regarding treatment options, and the overwhelming prevalence of mental disorders.



The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034"

*The Business Research  
Company*

The Business  
Research Company

The Business Research Company



What Is The Current Size And Anticipated Growth Of The [Treatment-Resistant Depression Market?](#)

The treatment-resistant depression market size is anticipated to experience strong growth in the near future, estimated to reach \$2.46 billion in 2029 at a CAGR of 6.9%. Key growth factors include an increase in chronic diseases, rising prevalence of anxiety disorders, growing awareness of mental health, heightened government initiatives, and

increased healthcare expenditure. Additionally, the future market trends will be shaped by telemedicine and digital health expansion, advancements in diagnostic and therapeutic technologies, mental health awareness, stigma reduction, the adoption of personalized medicine, and the use of artificial intelligence.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=23546&type=smp>

## How Is The High Prevalence Of Mental Disorders Influencing The Treatment-Resistant Depression Market Trends?

The high prevalence of mental disorders is a primary driver for the growth of the treatment-resistant depression market. Mental disorders, characterized by significant impairment in an individual's cognitive, emotional, and behavioral functioning, are influenced by factors such as genetic predisposition. This inherited vulnerability can affect brain chemistry and heighten susceptibility to conditions like depression, anxiety, and schizophrenia. The supportive role of treatment-resistant depression TRD therapies in such situations is to encourage the use of more personalized and advanced treatments when standard therapies prove inadequate, improving chances of recovery and quality of life.

## Which Are The Prominent Industry Players In The Treatment-Resistant Depression Market?

Major companies operating in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, GlaxoSmithKline GSK plc., Hikma Pharmaceuticals plc, Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, Lykos Therapeutics, Reviva Pharmaceuticals, Celon Pharma SA, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., and Reunion Neuroscience.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/treatment-resistant-depression-global-market-report>

## What Are Some Emerging Trends Within The Treatment-Resistant Depression Market?

Companies within the treatment-resistant depression market are focusing on the development of innovative therapies such as monotherapy to address unmet patient needs, enhance efficacy, and reduce side effects. Monotherapy provides more focused treatment that could be more effective for patients unresponsive to multiple medications. A prime example is SPRAVATO esketamine nasal spray, developed by Johnson & Johnson Services Inc. and approved by the U.S. Food and Drug Administration in January 2025. This rapid-acting treatment for adults with TRD is used alongside an oral antidepressant and works by targeting the brain's NMDA receptors, enhancing mood within hours.

## How Is The Treatment-Resistant Depression Market Segmented?

The treatment-resistant depression market in this report is segmented by:

- 1 Drug Class: Selective Serotonin Reuptake Inhibitors SSRIS, Monoamine Oxidase Inhibitors, Tricyclic Antidepressant, Psychedelics, Other Drug Classes
- 2 Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3 Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4 End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments include various types of antidepressants and psychedelics, providing a comprehensive view of available treatments.

What Are The Regional Insights Into The Treatment-Resistant Depression Market?

In 2024, North America was the largest region in the treatment-resistant depression market. However, the Asia-Pacific region is expected to be the fastest-growing area throughout the forecast period. This report loans insight into the treatment-resistant depression markets in Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse For More Similar Reports-

Point-of-Care Diagnostics Devices And Equipment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report>

Dental Diagnostic Imaging Devices And Equipment Global Market Report

<https://www.thebusinessresearchcompany.com/report/dental-diagnostic-imaging-devices-and-equipment-global-market-report>

Antidepressants Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/antidepressant-global-market-report>

[About The Business Research Company](#)

Learn More About The Business Research Company. Offering comprehensive, data-rich research and insights from over 15000+ reports across 27 industries and covering 60+ geographies. Equipped with 1,500,000 datasets, The Business Research Company provides unique insights from industry leaders helping you stay ahead in the race.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_f10rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham  
The Business Research Company  
+44 20 7193 0708

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/817120837>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.